Research Article

Novel Model to Predict the Prognosis of Patients with Stage II–III Colon Cancer

Yansong Xu,1,2 Fangfang Liang,1,2 Yi Chen,1,2 Zhen Wang,1,2 Huage Zhong,1,2 and Weizhong Tang1,2

1Guangxi Clinical Research Center for Colorectal Cancer, Nanning, Guangxi Zhuang Autonomous Region 530021, China
2Department of Gastrointestinal Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi Zhuang Autonomous Region 530021, China

Correspondence should be addressed to Weizhong Tang; tangweizhong0771@163.com

Received 2 September 2020; Revised 25 October 2020; Accepted 10 November 2020; Published 23 November 2020

Academic Editor: Maria Irene Bellini

Copyright © 2020 Yansong Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Different opinions exist on the relationship between the C-reactive protein-to-albumin ratio (CAR) and the prognosis of colon cancer. This study is aimed at evaluating the relationship between CAR and prognosis of stage II–III colon cancer and establishing a clinical prognosis model. Patients were randomised to a training set (566 cases) and validation set (110 cases). The relationship between CAR and clinicopathological variables was calculated, and the Kaplan-Meier method was used to analyse the overall survival (OS) rate of colon cancer. In the training set, colon cancer independent risk factors were included in the prognosis model and then tested in the validation set. The accuracy and discrimination of the model were assessed using the C-index and calibration curves. Compared with patients with low CAR, patients with high CAR showed significantly poorer survival (P = 0.020). In the multivariate analysis, CAR, carcinoembryonic antigen (CEA), lymph node metastasis, operation mode, and perineural invasion were identified as independent prognostic indicators and adopted to establish the prediction model. The C-index of the nomogram for predicting OS reached 0.751 in the training set and 0.719 in the validation set. The calibration curve exhibited good consistency. In the present study, the CAR may be an independent prognostic factor for stage II–III colon cancer, and the nomogram has a certain predictive value. However, further prospective large-sample research needs to be conducted to validate our findings.

1. Introduction

Colon cancer has the fourth highest incidence of all tumours and is the fifth leading cause of cancer deaths worldwide [1]. Clinical and pathological data, including age, sex, tumour site, AJCC TNM stage, and the number of lymph node dissection (LND), have been shown to correlate with survival outcomes. Thus, considerable attention has been paid to preoperative biomarkers and tumour prognosis evaluation. Systemic inflammatory biomarkers, such as PLR, NLR, and C-reactive protein-to-albumin ratio (CAR), have been recently reported to be closely related to a patient’s prognosis in colorectal carcinoma (CC), but the relationship is not well defined [2–5]. Which systemic inflammatory biomarker is most associated with the prognosis remains unclear. Patients with stage I CC have a good prognosis; however, those with stage IV CC who also present with an inflammatory response carry tumours with more aggressive biological behaviour and poorer survival [6]. The relationship between the prognosis of stage II or III colon cancer and inflammatory factors is not well defined. In addition, a single factor does not seem sufficient to predict prognosis. Hence, our group determined that combining factors would allow better prognostic prediction. Because these biomarkers are easily obtained from routine preoperative examinations, they have attracted increasing attention. To our knowledge, this is the first time that our hospital has established a model to evaluate the prognosis of patients with CC.

A nomogram is a two-dimensional graphic calculator that can conveniently diagnose diseases and rapidly evaluate prognosis. In addition to the conventional AJCC standard, clinicians can even collect the medical history of colon cancer.
patients and pre-/postoperative laboratory tests to predict patients' death risk. The present study assessed the prognostic value of CAR in patients and established a life nomogram to predict the 1- and 3-year overall survival (OS) rate of patients with stage II–III colon cancer.

2. Materials and Methods

2.1. Database and Candidate Variables. All patients underwent tumour resection and were diagnosed with colon cancer after the operation. Patients who met the following inclusion criteria were enrolled: (1) postoperative pathological diagnosis confirmed adenocarcinoma, (2) performance of resection for colon tumours, (3) patients undergoing limited operation, (4) follow-up at least 6 months after the operation, and (5) patients with stage II–III colon cancer. The exclusion criteria were as follows: (1) patients undergoing emergency operation, (2) patients with preoperative radiotherapy or chemotherapy, (3) history of tumour surgery, (4) patients with palliative operation, and (5) clinical diagnosis of hereditary nonpolyposis colorectal cancer or familial adenomatous polyposis clinical diagnosis of hereditary nonpolyposis colorectal cancer or familial adenomatous polyposis. Obstruction is defined as the inability of the colonoscope to pass through the intestine and the dilatation of the proximal intestine. All procedures were conducted following the ethical standards declared by the medical association. Given the retrospective nature of the study, the requirement of informed consent was waived, and patient data were kept confidential. This study was approved by the Institutional Review Board and Independent Ethics Committee of Cancer Hospital to Guangxi Medical University. The variables selected in this paper include clinicopathological data and biomarkers (Table 1). All 566 patients have complete follow-up records, including telephone, e-mail, SMS, and WeChat.

2.2. Determination of Variable Cutoff. The survival receiver operating characteristic (ROC) curve was used for statistical analysis by IBM SPSS 26.0 software. The point that lies closest to the upper left-hand corner of the graph is chosen as the cutoff. The cutoff point of CAR was 0.14.

2.3. Univariate and Multivariate Analyses. The following variables for univariate associations with OS were analysed: (1) clinical and pathological data: age (continuous), sex (male/female), BMI (continuous), tumour site (left/right), postoperative chemotherapy (absent/present), LNDs (continuous), operation mode (open/laparoscopic), intestinal obstruction (absent/present), ASA grade (1/2/3), preoperative comorbidity (absent/present), T-stage (T1–2/T3/T4), lymph node metastasis (LNM; absent/present), lymphovascular invasion (absent/present), and perineural invasion (PNI) (absent/present) and (2) laboratory markers: CEA (continuous), CA199 (continuous), CAR (≥0.14/0.14), PLR (continuous), and NLR (continuous). Finally, variables that showed statistical significance at P value < 0.05, including CAR, CEA, LNDs, LNM, and PNI, were used in multivariable modelling.

2.4. Model Construction and Validation. We built a training set with 566 patients. Multivariate Cox proportional hazards models of OS were formulated from all variables and two-way interactions, showing statistically significant correlations with their respective endpoints. If a variable's influence has a clinical difference in the level of interaction, it will reach clinical significance. The final model, including all significant and pairwise interactions, was still statistically significant (P < 0.05) and clinically significant after a backward stepwise method. On the basis of the final model, nomograms (calculators) of 1- and 3-year OS probability were constructed with the R software package. We extracted 110 patients from the test data set to form a validation set. The performance of the nomogram model was evaluated in the validation set by examining calibration and discrimination. On the basis of

| Variables | Training | Validation |
|-----------|----------|------------|
| Sex       | Male     | 353        | 89         |
|           | Female   | 213        | 41         |
| Age       | <60      | 303        | 61         |
|           | ≥60      | 263        | 49         |
| Tumour site| Left colon | 285    | 50         |
|           | Right colon | 281    | 60         |
| BMI (kg/m²)| Absent | 21.3       | 21.0       |
| Intestinal obstruction | Present | 463 | 82 |
|           | 1         | 295        | 54         |
| ASA grade | 2         | 235        | 45         |
|           | 3         | 36         | 11         |
| Comorbidities | Present | 514 | 98 |
| PLR       | 206      | 214        |
| NLR       | 3.2      | 4.5         |
| CAR       | <0.14    | 242        | 41         |
|           | ≥0.14    | 324        | 69         |
| CEA (median, mg/ml)| Absent | 15.6 | 15.4 |
|           | Present  | 38         | 29         |
| Postoperative chemotherapy | Absent | 124 | 14 |
|           | Present  | 442        | 96         |
| Operation mode | Open | 170 | 27 |
| LNDs      | 19       | 17         |
| T1-2      | 30       | 5          |
| T-stage   | T3       | 212        | 42         |
|           | T4       | 324        | 63         |
| LNM       | Absent   | 348        | 67         |
|           | Present  | 218        | 43         |
| LVI       | Absent   | 285        | 69         |
|           | Present  | 281        | 41         |
| PNI       | Absent   | 247        | 39         |
|           | Present  | 319        | 71         |

LND: lymph node dissection; LNM: lymph node metastasis; LVI: lymphovascular invasion; PNI: perineural invasion.
multivariate Cox proportional regression analysis, the variables with \( P < 0.05 \) were used to establish a nomogram. In the internal calibration plots, points parallel to the reference line represent covariates with similar prediction results in the training and validation sets.

### 2.5. Statistical Analysis

The Kaplan-Meier method was used for survival analysis by IBM SPSS 26.0 software (version 26.0; SPSS, Chicago, IL). Statistical significance was set at 0.05. We developed the prognostic model with univariate predictive variables evaluating the significance of each clinicopathological biomarker. Next, multivariate analyses were performed using the Cox proportional hazards model. Univariate predictive variables with \( P < 0.05 \) were applied to multivariate analyses in order to identify the independent prognostic factors. Nomogram and calibration plots were constructed using R software, version 3.3.3 (CRAN; R Foundation for Statistical Computing, Vienna, Austria) [7].

### 3. Results

#### 3.1. Patient Characteristics

After strict screening, 566 clinical cases were included in the training set, and 110 in the validation set. The median OS time was 36.2 months (range 6–130). The 6-month, 1-year, and 3-year follow-up rates were 100%, 87%, and 42%, respectively. The clinical data and laboratory results of all patients are summarised in Table 1. Table 2 shows the relationship between CAR

### Table 2: Demographic and clinicopathological characteristics of stage II-III colon cancer patients with CAR.

| Variables                  | Low CAR (<0.14) | High CAR (≥0.14) | \( P \) value |
|----------------------------|-----------------|------------------|--------------|
| Sex                        | Male            | 136              | 217          | 0.009       |
|                           | Female          | 106              | 107          |             |
| Age (median, year)         | 60 (16-89)      | 57 (16-88)       | 62 (19-89)   | 0.884       |
| Tumour site                | Left            | 131              | 154          | 0.120       |
|                           | Right           | 111              | 170          |             |
| BMI (kg/m\(^2\))           | 21.3 (8.6-43)   | 21.2 (8.9-41.3)  | 21.3 (8.6-43) | 0.366       |
| Tumour diameter            | 5.4 (1-15)      | 5.4 (2-8)        | 5.4 (1-15)   | <0.001      |
|                           | 1               | 172              | 123          | 0.212       |
| ASA grade                  | 2               | 122              | 113          |             |
|                           | 3               | 15               | 21           |             |
| Comorbidities              | Diabetes        | 23               | 21           | 0.225       |
|                           | Pneumonia       | 10               | 18           |             |
|                           | Hypertension    | 22               | 26           |             |
|                           | Heart disease   | 3                | 4            |             |
| Intestinal obstruction     | Absent          | 50               | 74           | 0.535       |
|                           | Present         | 192              | 250          |             |
| PLR                        | 206 (55-1113)   | 211 (55-355)     | 200 (134-1113) | <0.001     |
| NLR                        | 3.2 (0.53-196)  | 3.5 (0.57-193)   | 3.0 (0.53-196) | 0.547      |
| CEA (median, mg/ml)        | 3.5 (0.2-1500)  | 3.3 (0.2-1500)   | 5.4 (0.37-1000) | 0.043      |
| CA199 (median, mg/ml)      | 12 (0-1200)     | 11.2 (0.10-1200) | 13.4 (0.00-1200) | 0.672      |
| Postoperative chemotherapy | Absent          | 209              | 254          | 0.015       |
|                           | Present         | 33               | 70           |             |
| Operation mode             | Open            | 55               | 115          | 0.001       |
| LNDs                       | 19 (1-80)       | 18 (1-80)        | 19 (1-56)    | 0.121       |
| LNM                        | Absent          | 131              | 217          |             |
|                           | Present         | 110              | 107          |             |
| T-stage                    | T3              | 81               | 131          |             |
|                           | T4              | 150              | 174          |             |
| LVI                        | Absent          | 149              | 208          | 0.522       |
|                           | Present         | 93               | 116          |             |
| PNI                        | Absent          | 98               | 149          | 0.192       |
|                           | Present         | 144              | 175          |             |

LND: lymph node dissection; LNM: lymph node metastasis; LVI: lymphovascular invasion; PNI: perineural invasion.
and clinicopathological parameters. CEA, tumour diameter, and preoperative PLR affected the preoperative CAR level. In the training set, the 6-month, 1-year, and 3-year OS rates after radical resection were 100%, 98%, and 87%, respectively (no survival chart is provided).

3.2. Univariate and Multivariate Analyses of Clinical Variables Associated with OS in the Training Set. The relationships between variables and OS for colon cancer are listed in Table 3. In univariate analysis, OS was obviously related to the following factors: CAR \( (P = 0.022) \), CEA \( (P = 0.011) \), CA199 \( (P < 0.001) \), postoperative chemotherapy \( (P < 0.001) \), LNM \( (P < 0.001) \), operation mode \( (P = 0.041) \), LVI \( (P = 0.002) \), and PNI \( (P < 0.001) \). Patients with a lower CAR had a favorable prognosis for OS (Figure 1).

The results of the multivariate analysis of clinical and laboratory parameters correlated with OS are shown in Table 3. CAR \( (P = 0.002) \), CEA \( (P = 0.016) \), LNM \( (P < 0.001) \), operation mode \( (P = 0.041) \), and PNI \( (P = 0.012) \) were significantly associated with OS.

3.3. Construction and Verification of a Nomogram for OS. Figure 2 shows a nomogram constructed by independent risk factors after multivariate Cox analysis for OS in the training set. In the training and validation sets, the nomogram’s C-indices for prediction of OS were 0.751 and 0.719, respectively. For both sets, the calibration curves for 1- or 3-year OS exhibited high consistency between predicted values by the nomogram and the actual observations in the validation set (Figures 3 and 4).

### Table 3: Univariate analysis and multivariate analysis in the training set.

| Variables                        | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                 | HR                  | 95% CI                | \( P \) value | HR                  | 95% CI                | \( P \) value |
| Sex                              | Male ref            | —                     | —            | Male ref            | —                     | —            |
|                                  | Female              | —                     | —            | Female              | —                     | —            |
| Age (median, y)                  | 59                  | 0.996                 | 0.978-1.014  | 0.658               | 1.022                 | 0.999-1.044  | 0.907 |
| Tumour site                      | Left ref            | —                     | —            | Left ref            | —                     | —            |
|                                  | Right               | 1.066                 | 0.663-1.712  | 0.793               | 1.066                 | 0.663-1.712  | 0.793 |
| BMI (kg/m\(^2\))                 | 21.3                | 1.001                 | 0.964-1.039  | 0.957               | 1.000                 | 0.964-1.039  | 0.957 |
| Tumour diameter                  | 5.3                 | 0.980                 | 0.970-1.015  | 0.745               | 1.000                 | 0.970-1.015  | 0.745 |
| ASA grade                        | 3                   | 0.711                 | 0.495-1.110  | 0.425               | 0.991                 | 0.570-1.700  | 0.991 |
| Comorbidities                    | Absent ref          | —                     | —            | Absent ref          | —                     | —            |
|                                  | Present             | 1.011                 | 0.799-1.103  | 0.375               | 0.996                 | 0.787-1.244  | 0.658 |
| Intestinal obstruction           | Absent ref          | —                     | —            | Absent ref          | —                     | —            |
|                                  | Present             | 0.666                 | 0.395-1.120  | 0.125               | 0.999                 | 0.489-2.074  | 0.999 |
| PLR                              | 206                 | 1.001                 | 0.999-1.003  | 0.295               | 0.999                 | 0.997-1.001  | 0.999 |
| NLR                              | 3.2                 | 1.002                 | 0.976-1.028  | 0.906               | 0.999                 | 0.983-1.016  | 0.999 |
| CAR                              | <0.14 ref           | —                     | —            | <0.14 ref           | —                     | —            |
|                                 | \( \geq 0.14 \)     | 1.785                 | 1.086-2.933  | 0.022               | 2.271                 | 1.345-3.834  | 0.002 |
| CEA (median)                     | 0.2                 | 1.002                 | 1.001-1.004  | 0.011               | 1.002                 | 1.001-1.003  | 0.003 |
| CA199 (median)                   | 11.99               | 1.002                 | 1.001-1.004  | <0.001              | 1.002                 | 1.001-1.004  | <0.001 |
| Postoperative chemotherapy       | Absent ref          | —                     | —            | Absent ref          | —                     | —            |
|                                  | Present             | 2.561                 | 1.584-4.140  | <0.001              | 2.545                 | 1.530-4.235  | <0.001 |
| Operation mode                   | Open ref            | —                     | —            | Open ref            | —                     | —            |
|                                  | Laparoscopic        | 0.580                 | 0.360-0.934  | 0.025               | 0.601                 | 0.368-0.980  | 0.041 |
| LNDs                             | 19                  | 0.983                 | 0.608-1.591  | 0.944               | 0.999                 | 0.608-1.591  | 0.944 |
| LNM                              | Absent ref          | —                     | —            | Absent ref          | —                     | —            |
|                                  | Present             | 2.561                 | 1.584-4.140  | <0.001              | 2.545                 | 1.530-4.235  | <0.001 |
| T-stage                          | T3                  | 0.879                 | 0.625-1.237  | —                   | —                     | —            |
|                                  | T4                  | 0.913                 | 0.589-1.415  | 0.048               | 0.913                 | 0.589-1.415  | 0.048 |
| LVI                              | Absent ref          | —                     | —            | Absent ref          | —                     | —            |
|                                  | Present             | 2.178                 | 1.341-3.538  | 0.002               | 2.178                 | 1.341-3.538  | 0.002 |
| PNI                              | Absent ref          | —                     | —            | Absent ref          | —                     | —            |
|                                  | Present             | 2.426                 | 1.384-4.252  | 0.002               | 2.426                 | 1.384-4.252  | 0.002 |

LND: lymph node dissection; LNM: lymph node metastasis; LVI: lymphovascular invasion; PNI: perineural invasion.
Figure 1: Kaplan-Meier curves for OS by the presence of CAR.

Figure 2: The life nomogram to predict OS rate after surgical resection for stage II-III colon cancer.

Figure 3: Calibration curves for 1-year prediction in the validation set.
4. Discussion

This is a single-centre study that evaluated the correlations between OS and 20 variables in stage II–III colon cancer patients after operation, including inflammation biomarkers and clinicopathological parameters. This study confirmed that CAR, CA199, CEA, operation mode, postoperative chemotherapy, LNM, LVI, and PNI were related to the prognosis in univariate analysis. Finally, CAR, CEA, LNM, operation mode, and PNI were independent prognostic indicators in multivariate analysis. Using the above variables, we established a visual nomogram model. Moreover, the nomogram has been well verified in the internal validation set. The calibration plot points are almost parallel to the reference line.

Inflammation biomarkers, including PLR, NLR, and CAR, play different evaluation roles and can predict the prognosis and complications in patients with radical colon cancer [8, 9]. The increase of preoperative CRP reflects the ongoing inflammatory reaction and is related to the decrease of lymphocytes, which leads to the impairment of cell-mediated immune function in patients with colorectal cancer [10]. In cancer patients, malnutrition or nutrition consumption usually shows hypoproteinaemia, which is related to an increased risk of postoperative infection complications [10, 11]. In studying the predictive factors, CAR showed to be valuable in the survival analysis of colon cancer. Given that CAR was a continuous variable, ROC curves were used to establish the CAR cutoff value in our study. We defended that this was the best way to create two groups (high and low CAR) for a given sample with suitable sensitivity and specificity levels. The cutoff point of CAR was much higher than those of Hashimoto et al. and Ishizuka et al. [12, 13]. One possible explanation was the inconsistent inclusion criteria, such as the TNM stage, age, and tumour site. In the present study, CAR is related to sex, tumour site, obstruction, PLR, NLR, and operation mode. The nomogram shows that other factors, such as age, CEA, and operation mode, weaken the weight of CAR in influencing prognosis. We also concluded that low CAR has a better OS than high CAR, similar to previously reported findings [9, 12, 14]. CAR is a routine clinical examination, which is easy to be obtained. It is expected to become a promising biomarker for evaluating the prognosis of colon cancer patients.

An elevated serum CEA level is commonly seen in patients with solid tumours, especially in the digestive tract. Similar to other studies [15–18], preoperative CEA levels were independent prognostic factors in stage II–III colon cancer in this present study, whilst elevated preoperative CEA levels were negatively correlated with prognosis. Moreover, increased postoperative CEA was related to the recurrence and distant metastasis of colorectal cancer [15, 19]. The latest AJCC guidelines did not regard preoperative CEA as a high-risk factor affecting stage II colon cancer prognosis. Spindler et al. suggested that elevated preoperative CEA is a high-risk feature of stage II colorectal cancer [15, 19]. Quah et al. identified that patients with elevated preoperative CEA should receive preoperative chemotherapy [20]. Unlike some research results, the CAR’s cutoff value was 0.14 in the present study, which was obviously lower than those of some reported results [2, 15, 16]. Considering that CEA is a continuous variable, information loss will occur in variable data conversion. Hence, we did not assign the CEA value as a binary variable, which can reduce the prediction model’s error.

Compared with open surgery, laparoscopic or robot-assisted colectomies were 1.5–2.5 times more likely to achieve adequate LNDs [21]. Studies have shown that the number of LNDs is related to survival rates. The long-term curative effect of the laparoscopic group was obviously better than that of the traditional open group. The reason may be explained by the decreased postoperative complication rates and blood transfusions with better preservation of the early postoperative cellular immune response in LCCS. Compared with open surgery, patients displayed higher CD8+ counts postoperatively and lower plasma levels of CRP [22]. Moreover, in an animal model study, the postoperative serum interleukin-6 in the laparotomy group increased significantly [23].

![Figure 4: Calibration curves for 3-year prediction in the validation set.](image-url)
One hundred and fifty years ago, Cruveilhier first proposed the concept of tumour nerve infiltration. More and more studies emphasised the influence of PNI on prognosis. PNI is another way of colon cancer metastasis besides the blood supply and lymphatic metastasis and seems a reasonable risk factor. As a predictive and independent prognosis factor of the oncological outcomes in colon cancer, especially in stage II–III colon cancer, PNI was considered a high-risk factor for disease recurrence [24, 25]. Therefore, postoperative chemotherapy was strongly recommended for these patients to improve survival [26, 27]. In a previous study, the incidence of PNI was 56%, which was significantly higher than that reported by other authors [25, 28]. Including T4 (57%) colon may be the reason for this high value, and this also explains why we calculated the 3-year OS rate.

At present, standard clinical scoring systems usually use individual factors to evaluate prognosis risk. They have the advantage of simplicity and convenience. However, because each risk factor’s weight is equal and the interaction of individual risk factors is not considered, their accuracy is not optimal. The influence of interaction between variables on prognosis is not considered. The nomogram helps to avoid these shortcomings. As a visual tool, it can provide more accurate prediction results for specific patients. In the occurrence, outcome, prognosis, and recurrence of diseases, a nomogram has rich clinical application value and is gradually adopted by clinicians.

In the nomograph, each variable corresponds to a point in the line. Then, the point is used as the intersection point perpendicular to the top line, which is the variable’s fraction. Add up all the points, and the total score is the final predicted value. Clinicians can obtain each variable, so the prediction tool is practical and convenient. In this study, we investigated 20 variables of clinical and haematological parameters potentially related to prognosis. Amongst them, five variables could independently predict prognosis. Thus, the nomogram constitutes a cheap tool for evaluating the prognosis. In the internal verification data set, the nomogram’s prediction accuracy and discrimination ability were well verified, indicating its excellent performance.

The shortcomings of this study still cannot be ignored. Firstly, selective bias exists in a single-centre retrospective study. Secondly, all laboratory parameters were only preoperative test results. Clinicians need to pay attention to the changes in preoperative and postoperative test results. Thirdly, because the nomogram model’s establishment requires complete data, cases with incomplete data will be excluded, which may lead to selection bias. Finally, we did not validate the prediction model using external data, and we need to check our prediction model against external data in the future.

5. Conclusion

As a novel biomarker, CAR is an independent factor affecting stage II–III colon cancer and is negatively correlated with prognosis. The life nomogram model can help doctors make further treatment plans for colon cancer patients after surgery.

Data Availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Yansong Xu and Fangfang Liang contributed equally to this work.

Acknowledgments

This work was supported by the (1) National Natural Science Foundation of China (81973533), (2) 2019 Guangxi University High-level Innovation Team and the Project of Outstanding Scholars Program, and (3) Guangxi Science and Technology Project (2019AC03004 and AD19245197).

References

[1] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” Ca A Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.
[2] S. Yatabe, K. Eto, K. Haruki et al., “Significance of systemic immune-inflammation index for prediction of prognosis after resecting in patients with colorectal cancer,” International Journal of Colorectal Disease, vol. 35, no. 8, pp. 1549–1555, 2020.
[3] S. C. Lee, J. W. Huh, W. Y. Lee et al., “Prognostic value of serum inflammatory markers in colorectal cancer,” International Journal of Colorectal Disease, vol. 35, no. 7, pp. 1211–1219, 2020.
[4] M. Bailon-Cuadrado, E. Choolani-Bhojwani, F. J. Tejero-Pinto et al., “Preoperative platelet–lymphocyte ratio is an independent factor of poor prognosis after curative surgery for colon cancer,” Updates in Surgery, vol. 70, no. 1, pp. 33–39, 2018.
[5] Z. Hu, S. Tan, S. Chen et al., “Diagnostic value of hematological parameters platelet to lymphocyte ratio and hemoglobin to platelet ratio in patients with colon cancer,” Clinica Chimica Acta, vol. 501, pp. 48–52, 2020.
[6] D. Gomez, G. Morris-Stiff, J. Wyatt, G. J. Toogood, J. P. A. Lodge, and K. R. Prasad, “Surgical technique and systemic inflammation influences long-term disease-free survival following hepatic resection for colorectal metastasis,” Journal of Surgical Oncology, vol. 98, no. 5, pp. 371–376, 2008.
[7] J. Oksanen, Vegan: community ecology package. Ver. 1.8-3, R Development Core Team 2006. R: a language and environment for statistical computing, 2006.
[8] M. Zengin, “Local Inflammatory Response Can Predict Clinical Outcome in Patients with Curatively Resected Stage-IIB Colon Cancer: An Advanced Methodological Study,” Pathology & Oncology Research, vol. 26, no. 3, pp. 1805–1816, 2020.
[9] S. Suzuki, T. Akiyoshi, K. Oba et al., “Comprehensive Comparative Analysis of Prognostic Value of Systemic Inflammatory...
Biomarkers for Patients with Stage II/III Colon Cancer,” *Annals of Surgical Oncology*, vol. 27, no. 3, pp. 844–852, 2020.

[10] L. H. Moyes, E. F. Leitch, R. F. Mckee, J. H. Anderson, P. G. Horgan, and D. C. Mcmillan, “Preoperative systemic inflammation predicts postoperative infectious complications in patients undergoing curative resection for colorectal cancer,” *British Journal of Cancer*, vol. 100, no. 8, pp. 1236–1239, 2009.

[11] L. De Magistris, B. Paquette, D. Orry et al., “Preoperative inflammation increases the risk of infection after elective colorectal surgery: results from a prospective cohort,” *International Journal of Colorectal Disease*, vol. 31, no. 9, pp. 1611–1617, 2016.

[12] S. Hashimoto, T. Tominaga, T. Nonaka et al., “The C-reactive protein to albumin ratio predicts postoperative complications in oldest-old patients with colorectal cancer,” *International Journal of Colorectal Disease*, vol. 35, no. 3, pp. 423–431, 2020.

[13] M. Ishizuka, H. Nagata, K. Takagi, Y. Iwasaki, and K. Kubota, “Clinical Significance of C-Reactive Protein-to-Albumin Ratio with Rectal Cancer Patient Undergoing Chemoradiotherapy Followed by Surgery,” *Annals of Surgical Oncology*, vol. 37, no. 10, pp. 5797–5804, 2017.

[14] R. D. Dolan, S. T. McSorley, J. H. Park et al., “The prognostic value of systemic inflammation in patients undergoing surgery for colon cancer: comparison of composite ratios and cumulative scores,” *British Journal of Cancer*, vol. 119, no. 1, pp. 40–51, 2018.

[15] T. Konishi, Y. Shimada, M. Hsu et al., “Association of Preoperative and Postoperative Serum Carcinoembryonic Antigen and Colon Cancer Outcome,” *JAMA Oncology*, vol. 4, no. 3, pp. 309–315, 2018.

[16] O. Margalit, R. Mamanti, Y.-X. Yang et al., “Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancer,” *European Journal of Cancer*, vol. 94, pp. 1–5, 2018.

[17] A. Z. Becerra, C. P. Probst, M. A. Tejani et al., “Evaluating the Prognostic Role of Elevated Preoperative Carcinoembryonic Antigen Levels in Colon Cancer Patients: Results from the National Cancer Database,” *Annals of Surgical Oncology*, vol. 23, no. 5, pp. 1554–1561, 2016.

[18] B. A. Spindler, J. R. Bergquist, C. A. Thiels et al., “Incorporation of CEA Improves Risk Stratification in Stage II Colon Cancer,” *Journal of Gastrointestinal Surgery*, vol. 21, no. 5, pp. 770–777, 2017.

[19] H. Kim, H. I. Jung, S. H. Kwon et al., “Preoperative neutrophil-lymphocyte ratio and CEA is associated with poor prognosis in patients with synchronous colorectal cancer liver metastasis,” *Annals of Surgical Treatment and Research*, vol. 96, no. 4, pp. 191–200, 2019.

[20] H.-M. Quah, J. F. Chou, M. Gonen et al., “Identification of patients with high-risk stage II colon cancer for adjuvant therapy,” *Diseases of the Colon & Rectum*, vol. 51, no. 5, pp. 503–507, 2008.

[21] R. D. Dolan, S. T. McSorley, P. G. Horgan, and D. C. McMillan, “Determinants of lymph node count and positivity in patients undergoing surgery for colon cancer,” *Medicine*, vol. 97, no. 13, p. e185, 2018.

[22] A. Crucitti, M. Corbi, P. M. Tomaiuolo et al., “Laparoscopic surgery for colorectal cancer is not associated with an increase in the circulating levels of several inflammation-related factors,” *Cancer Biology & Therapy*, vol. 16, no. 5, pp. 671–677, 2015.

[23] M. Miguchi, M. Yoshimitsu, K. Hakoda et al., “Short-term outcomes of laparoscopic surgery in octogenarians with colorectal cancer: a single-institution analysis,” *Surgery Today*, vol. 48, no. 3, pp. 292–299, 2018.

[24] L. G. J. Leijssen, A. M. Dinaux, M. S. Taylor et al., “Perineural Invasion Is a Prognostic but not a Predictive Factor in Nonmetastatic Colon Cancer,” *Diseases of the Colon & Rectum*, vol. 62, no. 10, pp. 1212–1221, 2019.

[25] J. A. Cienfuegos, P. Martinez, J. Baixauli et al., “Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer,” *Annals of Surgical Oncology*, vol. 24, no. 4, pp. 1077–1084, 2017.

[26] M. K. Washington, J. Berlin, P. Branton et al., “Protocol for the Examination of Specimens From Patients With Primary Carcinoma of the Colon and Rectum,” *Archives of Pathology & Laboratory Medicine*, vol. 133, pp. 1551–1939, 2009.

[27] K. A. Mirkin, C. S. Holdenbeak, A. Mohamed, Y. Jia, W. S. El-Deiry, and E. Messaris, “Impact of perineural invasion on survival in node negative colon cancer,” *Cancer Biology & Therapy*, vol. 18, no. 9, pp. 740–745, 2017.

[28] J. W. Huh, H. R. Kim, and Y. J. Kim, “Prognostic Value of Perineural Invasion in Patients with Stage II Colorectal Cancer,” *Annals of Surgical Oncology*, vol. 17, no. 8, pp. 2066–2072, 2010.